What sets Curaderm apart from traditional skin cancer treatments is its ability to target cancer cells at a molecular level using plant-based compounds. Curaderm BEC5 is specifically designed to treat basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)—the two most common forms of skin cancer in the U.S.
The active ingredients in Curaderm come from a species of eggplant that contains solasodine glycosides, which are natural compounds that selectively target cancer cells. These glycosides attach to receptors only found on abnormal skin cells. Once attached, they trigger apoptosis, a process where the body’s own immune system breaks down and removes the unwanted cells.
Unlike treatments that destroy both healthy and cancerous tissue, Curaderm offers a more targeted, tissue-sparing approach. This makes it an appealing option for patients with superficial lesions on cosmetically sensitive areas like the face or chest.
Additionally, Curaderm’s mode of action makes it particularly suited for treating actinic keratosis, a precancerous condition often caused by sun exposure. Many users report not only a reduction in lesions but also improved skin texture after completing treatment.
The cream is typically applied twice a day under an occlusive dressing. While the skin may become red, inflamed, or scabbed during the healing phase, these are signs that the product is working as intended. Once treatment is complete, the skin typically heals with minimal scarring.
Curaderm offers a natural, science-based alternative that supports the body’s healing process without invasive intervention.